“tighter than a Tasmanian family reunion” hahah you’re a funny guy!
Ahem yeah I meant Q1 2019 but HC wouldn’t let my go back and change it. Yep I read the extensive Sprout8 report when it was first released.
IMO the biggest risks are competition (liquid biopsy is making big claims) and the risk that trials 6 & 7 don’t deliver. If we remain on schedule Colostat will hit market years before an equivalent liquid biopsy test is available. Based on all the previous work clinical trials should be successful and that’ll determine the value of this company. Let’s hope they hit a six in trial 6! I’d like to know their anticipated timeframe...
Ann: Final Antibody Selection Complete, page-8
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.033(25.4%) |
Mkt cap ! $15.41M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 9.7¢ | $114.8K | 1.082M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5500 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 164688 | 2 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| RHY (ASX) Chart |
